Diffusion MRI Changes Linked to α-Synuclein Seed Amplification Status in Parkinson’s Disease
Objective: To compare free-water (FW) imaging in individuals with Parkinson’s disease (PD), with positive vs. negative cerebrospinal fluid (CSF) α-synuclein seed amplification assay (SAA) status.…Seed amplification assay detects alpha-synuclein in cerebrospinal fluid in pre- and symptomatic autosomal dominant Alzheimer’s disease
Objective: To examine the ability to detect concurrent Lewy Body Disease via Lew Body pathology (LBP) in Autosomal Dominant Alzheimer’s Disease (ADAD) through detection of…A Multidimensional Biomarker Panel for The Early Detection of Parkinson’s Disease
Objective: To explore the potential of a multidimensional biomarker panel integrating motor, non-motor, biochemical, metabolic, genetic, and neuroimaging biomarkers to increase sensitivity and specificity of…Investigating the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In Vitro Models
Objective: This study aims to evaluate the neuroprotective potential of various mushroom extracts in in vitro models of PD. Background: Parkinson’s disease (PD) is a…Quantitative Measures of Cutaneous Phosphorylated Alpha-Synuclein: Powering a Disease Modification Clinical Trial In Parkinson’s Disease
Objective: To use a novel quantitative assessment of cutaneous P-SYN in a pilot study of patients with Parkinson’s disease (PD) and healthy volunteers (HVs) to…Differential Effect of alpha-Synuclein on Mitochondrial Morphology in PD and MSA
Objective: In this study, we investigated the morphology of mitochondria and localization of alpha-synuclein as driven by alpha-synuclein isolated from PD and MSA brain-derived tissue.…Description Genotype/phenotype of patients with Parkinson’s disease. Report of an Argentinean cohort included in the LARGE PD Consortium.
Objective: To characterize the genetic and phenotypic profile of Argentinean Parkinson's patients and contribute to the understanding of the genetic heterogeneity of this disease. Background:…Diagnostic mismatches between clinical assessment, imaging and alpha-synuclein biomarkers in parkinsonian syndromes
Objective: To analyze the frequency of matching information provided by traditional clinical assessment, dopamine transporter (DaTscan), and skin biopsy results in patients with undiagnosed parkinsonian syndromes. Background:…Parkinson’s Progression Markers Initiative (PPMI): A Biomarker Engine for Therapeutic Development for PD and Related Synucleinopathies
Objective: PPMI is a longitudinal, observational study investigating clinical, imaging, genetic and biofluid biomarkers to accelerate therapeutic development for Parkinson’s disease (PD) and related synucleinopathies…The neuroprotective effects of Echinacoside on α-synuclein fibril-induced Parkinson’s disease mice model
Objective: This study further investigates the ameliorative effects of ECH on neurobehavioral abnormalities and nigrostriatal dopaminergic system impairment in α-synuclein preformed fibrils (α-Syn PFFs)-induced PD…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 60
- Next Page »